Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
Status:
Completed
Trial end date:
2019-05-21
Target enrollment:
Participant gender:
Summary
This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled,
parallel-group study to examine the efficacy, safety, and pharmacokinetics of vedolizumab
(MLN0002) in induction and maintenance therapy in Japanese participants with moderately or
severely active Crohn's disease.